[HTML][HTML] Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data
P Puca, A Del Gaudio, J Iaccarino, V Blasi, G Coppola… - Cancers, 2025 - mdpi.com
The advent of Janus kinase (JAK) inhibitors, including tofacitinib, filgotinib, and upadacitinib,
has significantly widened the therapeutic options for patients with inflammatory bowel …
has significantly widened the therapeutic options for patients with inflammatory bowel …